COMP <GO>
IDXG vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
Interpace Biosciences Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: IDXG 4
— TMO 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: IDXG
LAST: $5.72 (+15.56%) • MKT CAP: $23.2M
roic
16.20%
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IDXG VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IDXG | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 16.20% | 9.30% | +6.90 | IDXG | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.7x | 30.4x | -25.70 | IDXG | /valuation <GO> |
| Free Cash Flow Yield | 23.60% | 2.40% | +21.20 | IDXG | /fcf-yield <GO> |
| Operating Margin | 10.50% | 17.40% | -6.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 63.50% | 15.10% | +48.40 | IDXG | /net-margins <GO> |
| Revenue Growth (YoY) | -17.50% | 3.90% | -21.40 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.50 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 62.9 | -12.95 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 36.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.2M | $262.22B | -$262.19B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IDXG REV | TMO REV | IDXG GROSS % | TMO GROSS % | IDXG FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $38.7M | $44.56B | 62.3% | — | $5.5M | $6.29B |
| FY 2024 | $46.9M | $42.88B | 63.8% | — | $3.8M | $7.27B |
| FY 2023 | $40.0M | $42.86B | — | — | $3.8M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IDXG // BETA —
TMO // BETA 0.94